Oncology Resource Group

Oncology Competitive Intelligence Leaders

About ONCrg

Oncology Resource Group’s experts provide best-in-class competitive intelligence to commercial, medical and scientific teams worldwide.

After a decade of experience from consulting for top-tier biopharma companies and a decade of operating our CVrg business unit, ONCrg was launched in 2013 by Stacey McCann, Nikki Trunnell and Michael Reynolds to fill a critical need from cancer drug developers for higher quality competitive intelligence than traditional agencies could deliver. ONCrg’s unique value add was built by dedicating talented analysts to one tumor area at a time and developing deep subject matter expertise to create and present essential CI resources. Over time, our analysts earned best-in-class CI distinctions from clients by covering medical conferences, delivering accurate competitive landscapes, and providing reliable insights about ongoing new data releases.
ONCrg employs highly skilled Ph.D. scientists with a deep understanding of clinical medicine and the ability to quickly integrate complex information into the elite CI resources our clients rely on.

By empowering talented scientists that intensely focus on oncology drug markets, and working hand-in-hand with clients to develop the most relevant forward-looking resources possible, we achieve new standards of analytical excellence and deliver the most accurate, insightful, and robust market planning resources available.

We are committed to helping our clients succeed in creating winning strategies and making the right business decisions for their new products, brands, franchises, partnerships, and alliances.

Through rigorous and sophisticated methodologies, our firm interprets numerous scientific, clinical, and therapy area developments on an ongoing basis and is adept at evaluating the commercial impact of complicated interconnected market events and how changes in treatment trends, patient populations, and risk factors will weigh into the future marketplace. Our fundamental belief is that clients are best served by our team’s full-time, exclusive study of oncology markets which enable the production of market planning resources that contain more depth, insight, and precision than would otherwise be possible.

Oncology Resource Group’s experts provide best-in-class competitive intelligence to commercial, medical and scientific teams worldwide.

After a decade of experience from consulting for top-tier biopharma companies and a decade of operating our CVrg business unit, ONCrg was launched in 2013 by Stacey McCann, Nikki Trunnell and Michael Reynolds to fill a critical need from cancer drug developers for higher quality competitive intelligence than traditional agencies could deliver. ONCrg’s unique value add was built by dedicating talented analysts to one tumor area at a time and developing deep subject matter expertise to create and present essential CI resources. Over time, our analysts earned best-in-class CI distinctions from clients by covering medical conferences, delivering accurate competitive landscapes, and providing reliable insights about ongoing new data releases.
ONCrg employs highly skilled Ph.D. scientists with a deep understanding of clinical medicine and the ability to quickly integrate complex information into the elite CI resources our clients rely on.

By empowering talented scientists that intensely focus on oncology drug markets, and working hand-in-hand with clients to develop the most relevant forward-looking resources possible, we achieve new standards of analytical excellence and deliver the most accurate, insightful, and robust market planning resources available.

We are committed to helping our clients succeed in creating winning strategies and making the right business decisions for their new products, brands, franchises, partnerships, and alliances.

Through rigorous and sophisticated methodologies, our firm interprets numerous scientific, clinical, and therapy area developments on an ongoing basis and is adept at evaluating the commercial impact of complicated interconnected market events and how changes in treatment trends, patient populations, and risk factors will weigh into the future marketplace. Our fundamental belief is that clients are best served by our team’s full-time, exclusive study of oncology markets which enable the production of market planning resources that contain more depth, insight, and precision than would otherwise be possible.

ALREADY A CLIENT? CLICK HERE TO REGISTER.

    Information and Sample Requests

    To learn more about our reports, services, and CI support, please fill out the form below or call us at 650.485.2626.

    *Please note, we will not share your details outside of our company


      Sample Request